Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary
Kidney International · 2026-09 · 110 (3) · 502-507
DOI: 10.1016/j.kint.2026.03.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026-09. Verfasst von Brad H Rovin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Complement Inactivating Agents, B-Lymphocytes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kidney Disease: Improving Global Outcomes (KDIGO) updated its clinical practice guideline for the management of glomerular diseases in 2021, more than a decade after the first glomerular diseases guideline was published, reflecting slow progress in drug development. But since then, novel therapies for several glomerular diseases have been successfully tested and approved by regulatory agencies, none more so than IgA nephropathy (IgAN). To keep pace with new therapies, the IgAN guideline was updated again in 2025. After this revision came to press, 3 additional IgAN treatments received accelerated approval by the US Food and Drug Administration. Because the presumptive mechanisms of action of 2 of these new therapies are mechanistically different from those of previously approved drugs, the KDIGO IgAN Work Group felt that a brief commentary outlining where the new therapies may fit into the overall IgAN treatment strategy was warranted in lieu of a full guideline update, pending additional evidence for these and other therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu.
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
- Department of Immunology and Inflammation, Imperial College London, London, UK.
- Renal Division, University of São Paulo Medical School, Sao Paulo, Brazil.
- Divsion of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Nephrology, Juntendo University, Tokyo, Japan.
Zitieren
APA
Rovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarchi, H., & Floege, J. (2026). Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary. Kidney International, 110(3), 502-507. https://doi.org/10.1016/j.kint.2026.03.003
Vancouver
Rovin BH, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, et al. Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary. Kidney International. 2026;110(3):502-507. doi:10.1016/j.kint.2026.03.003
BibTeX
@article{Rovin2026,
author = {Rovin, Brad H and Barratt, Jonathan and Cook, H Terence and Noronha, Irene L and Reich, Heather N and Suzuki, Yusuke and Tang, Sydney C W and Trimarchi, Hernán and Floege, Jürgen},
title = {Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary},
journal = {Kidney International},
year = {2026},
volume = {110},
number = {3},
pages = {502--507},
doi = {10.1016/j.kint.2026.03.003}
}
EUVIMED